Trial site
Ondokuz Mayis Univ. Med. Fac.
Samsun, 55139, TürkiyeNot linked to an institution yet
- 8running trials
- 4closed trials
The trials here
What the 12 trials at this site are about, from their registry records.
- Status
- Active, not recruiting7 trials
- Completed2 trials
- Terminated2 trials
- Recruiting1 trial
- Lead sponsor
- Hoffmann-La Roche8 trials
- Biogen1 trial
- BioMarin Pharmaceutical1 trial
- F2G Ltd1 trial
- Il-Yang Pharm. Co., Ltd.1 trial
Running trials
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT05296798· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
NCT04431726· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
NCT04434092· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
NCT04432584· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
NCT03958877· Phase 3· Biogen· Source
Recruiting
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
NCT03459534· Phase 3· Il-Yang Pharm. Co., Ltd.· Source
Contact: Na Yun Kim
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error